

VGI Health Technology Limited

Sydney New South Wales, 22 September 2021 – VGI Health Technology Limited (the **Company** or **VTL**) wishes to clarify a statement made in an NSX announcement released today about the release of the 2021 Annual Report to Shareholders.

The reference in the penultimate paragraph to Q1 of 2023 should read Q1 of 2022.

Authorised for release by the Company Secretary.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Castriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations
Ph: +61 (0) 419 788 431

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp